Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study.
Saved in:
| Title: | Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study. |
|---|---|
| Authors: | Szepietowski JC; Faculty of Medicine, University of Science and Technology, Wroclaw, Poland., Reich A; Department of Dermatology, Medical College of Rzeszów University, Rzeszów, Poland., Feldman SR; Department of Dermatology, Pathology and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA., Pulka G; Department of Dermatology, Centrum Medyczne All-med Badania Kliniczne, Kraków, Poland., Mekokishvili L; Petre Shotadze Tbilisi Medical Academy, School of Medicine, Tbilisi Cancer Center, Tbilisi, Georgia., Tsiskarishvili N; Department of Dermatology, Georgian-American University, Tbilisi, Georgia., Svarca I; Department of Dermatology, Health and Aesthetics LTD, Riga, Latvia., Poder A; Department of Dermatology, Kliiniliste Uuringute Keskus OU, Tartu Linn, Estonia., Singh G; Department of Dermatology, Biocon Biologics Limited, Bangalore, India., Deodhar S; Department of Dermatology, Biocon Biologics Limited, Bangalore, India., Kumar K; Department of Dermatology, Biocon Biologics Limited, Bangalore, India., Marwah A; Department of Dermatology, Biocon Biologics Limited, Bangalore, India., Loganathan S; Department of Dermatology, Biocon Biologics Limited, Bangalore, India., Athalye SN; Department of Dermatology, Biocon Biologics Limited, Bangalore, India., Wolff-Holz E; Clinical Development and Medical Affairs, Biocon Biologics UK Ltd, London, UK. |
| Source: | Expert opinion on biological therapy [Expert Opin Biol Ther] 2025 Aug; Vol. 25 (8), pp. 913-924. Date of Electronic Publication: 2025 Jul 29. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-7682 |
|---|---|
| DOI: | 10.1080/14712598.2025.2538608 |
